Definition der pharmakoresistenten Epilepsie: Konsensusvorschlag der ad hoc-Task Force der ILAE-Kommission für Therapeutische Strategien

Translated title of the contribution: Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies

P. Kwan, A. Arzimanoglou, A. T. Berg, M. J. Brodie, W. A. Hauser, G. Mathern, Solomon L. Moshe, E. Perucca, S. Wiebe, J. French

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To improve patient care and facilitate clinical research, the International League Against Epilepsy (ILAE) appointed a Task Force to formulate a consensus definition of drug resistant epilepsy. The overall framework of the definition has two hierarchical levels: Level 1 provides a general scheme to categorize response to each therapeutic intervention, including a minimum dataset of knowledge about the intervention that would be needed; Level 2 provides a core definition of drug resistant epilepsy using a set of essential criteria based on the categorization of response (from Level 1) to trials of antiepileptic drugs. It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. This definition can be further refined when new evidence emerges. The rationale behind the definition and the principles governing its proper use are discussed, and examples to illustrate its application in clinical practice are provided.

Original languageGerman
Pages (from-to)372-381
Number of pages10
JournalAktuelle Neurologie
Volume37
Issue number8
DOIs
StatePublished - 2010

Fingerprint

Advisory Committees
Epilepsy
Anticonvulsants
Patient Care
Appointments and Schedules
Seizures
Therapeutics
Research
Drug Resistant Epilepsy

Keywords

  • definition
  • drug resistance
  • epilepsy
  • international league against epilepsy
  • intractable
  • refractory

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Definition der pharmakoresistenten Epilepsie : Konsensusvorschlag der ad hoc-Task Force der ILAE-Kommission für Therapeutische Strategien. / Kwan, P.; Arzimanoglou, A.; Berg, A. T.; Brodie, M. J.; Hauser, W. A.; Mathern, G.; Moshe, Solomon L.; Perucca, E.; Wiebe, S.; French, J.

In: Aktuelle Neurologie, Vol. 37, No. 8, 2010, p. 372-381.

Research output: Contribution to journalArticle

Kwan, P, Arzimanoglou, A, Berg, AT, Brodie, MJ, Hauser, WA, Mathern, G, Moshe, SL, Perucca, E, Wiebe, S & French, J 2010, 'Definition der pharmakoresistenten Epilepsie: Konsensusvorschlag der ad hoc-Task Force der ILAE-Kommission für Therapeutische Strategien', Aktuelle Neurologie, vol. 37, no. 8, pp. 372-381. https://doi.org/10.1055/s-0030-1265943
Kwan, P. ; Arzimanoglou, A. ; Berg, A. T. ; Brodie, M. J. ; Hauser, W. A. ; Mathern, G. ; Moshe, Solomon L. ; Perucca, E. ; Wiebe, S. ; French, J. / Definition der pharmakoresistenten Epilepsie : Konsensusvorschlag der ad hoc-Task Force der ILAE-Kommission für Therapeutische Strategien. In: Aktuelle Neurologie. 2010 ; Vol. 37, No. 8. pp. 372-381.
@article{8a95aa267b474762ba5b19efc8a3528b,
title = "Definition der pharmakoresistenten Epilepsie: Konsensusvorschlag der ad hoc-Task Force der ILAE-Kommission f{\"u}r Therapeutische Strategien",
abstract = "To improve patient care and facilitate clinical research, the International League Against Epilepsy (ILAE) appointed a Task Force to formulate a consensus definition of drug resistant epilepsy. The overall framework of the definition has two hierarchical levels: Level 1 provides a general scheme to categorize response to each therapeutic intervention, including a minimum dataset of knowledge about the intervention that would be needed; Level 2 provides a core definition of drug resistant epilepsy using a set of essential criteria based on the categorization of response (from Level 1) to trials of antiepileptic drugs. It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. This definition can be further refined when new evidence emerges. The rationale behind the definition and the principles governing its proper use are discussed, and examples to illustrate its application in clinical practice are provided.",
keywords = "definition, drug resistance, epilepsy, international league against epilepsy, intractable, refractory",
author = "P. Kwan and A. Arzimanoglou and Berg, {A. T.} and Brodie, {M. J.} and Hauser, {W. A.} and G. Mathern and Moshe, {Solomon L.} and E. Perucca and S. Wiebe and J. French",
year = "2010",
doi = "10.1055/s-0030-1265943",
language = "German",
volume = "37",
pages = "372--381",
journal = "Aktuelle Neurologie",
issn = "0302-4350",
publisher = "Georg Thieme Verlag",
number = "8",

}

TY - JOUR

T1 - Definition der pharmakoresistenten Epilepsie

T2 - Konsensusvorschlag der ad hoc-Task Force der ILAE-Kommission für Therapeutische Strategien

AU - Kwan, P.

AU - Arzimanoglou, A.

AU - Berg, A. T.

AU - Brodie, M. J.

AU - Hauser, W. A.

AU - Mathern, G.

AU - Moshe, Solomon L.

AU - Perucca, E.

AU - Wiebe, S.

AU - French, J.

PY - 2010

Y1 - 2010

N2 - To improve patient care and facilitate clinical research, the International League Against Epilepsy (ILAE) appointed a Task Force to formulate a consensus definition of drug resistant epilepsy. The overall framework of the definition has two hierarchical levels: Level 1 provides a general scheme to categorize response to each therapeutic intervention, including a minimum dataset of knowledge about the intervention that would be needed; Level 2 provides a core definition of drug resistant epilepsy using a set of essential criteria based on the categorization of response (from Level 1) to trials of antiepileptic drugs. It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. This definition can be further refined when new evidence emerges. The rationale behind the definition and the principles governing its proper use are discussed, and examples to illustrate its application in clinical practice are provided.

AB - To improve patient care and facilitate clinical research, the International League Against Epilepsy (ILAE) appointed a Task Force to formulate a consensus definition of drug resistant epilepsy. The overall framework of the definition has two hierarchical levels: Level 1 provides a general scheme to categorize response to each therapeutic intervention, including a minimum dataset of knowledge about the intervention that would be needed; Level 2 provides a core definition of drug resistant epilepsy using a set of essential criteria based on the categorization of response (from Level 1) to trials of antiepileptic drugs. It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. This definition can be further refined when new evidence emerges. The rationale behind the definition and the principles governing its proper use are discussed, and examples to illustrate its application in clinical practice are provided.

KW - definition

KW - drug resistance

KW - epilepsy

KW - international league against epilepsy

KW - intractable

KW - refractory

UR - http://www.scopus.com/inward/record.url?scp=78549242718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549242718&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1265943

DO - 10.1055/s-0030-1265943

M3 - Article

AN - SCOPUS:78549242718

VL - 37

SP - 372

EP - 381

JO - Aktuelle Neurologie

JF - Aktuelle Neurologie

SN - 0302-4350

IS - 8

ER -